Home / Industry News / 2010 / Forbes India: How the Abbott-Piramal Deal Went Down

Forbes India: How the Abbott-Piramal Deal Went Down

Source: PharmaManufacturing.com

Jun 08, 2010

business.in.com

Print Email

Show More Content

More News:

Critics question Amarin fish oil study

11/12/2018

There’s something fishy about the positive results Amarin reported for its supplemental drug, Vascepa.
New CODP treatment gets FDA nod

11/12/2018

Mylan and Theravance Biopharma have won approval for their inhalable treatment, Yupelri.
Nestle ups stake in food allergy drug developer

11/12/2018

Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics, as the drug developer prepares to submit a marketing application for its peanut allergy treatment before the end of the year.
Sandoz recalls China-made blood pressure drug

11/12/2018

Novartis said its Sandoz division is recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug.
Sandoz abandons Rituxan biosim in U.S.

11/09/2018

Sandoz announced that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013.
AbbVie sues England’s NHS

11/09/2018

Abbvie is claiming England's National Health Service (NHS) breached procurement rules during the process of seeking suppliers for hepatitis C treatment.
BMS gets ready to layoff employees, shutter operations at ZymoGenetics facility

11/07/2018

Operations at Seattle-based ZymoGenetics, which is owned by Bristol-Myers Squibb, has been winding down for the last few years.
Experimental drug for rosacea meets late-stage goals

11/07/2018

Foamix announced positive results this week for its new treatment for a common skin problem.
AstraZeneca sells 3 more drugs for $350 million

11/06/2018

Covis Pharma will pay AstraZeneca $350 million for rights to Alvesco, Omnaris and Zetonna which are three older drugs for asthma and rhinitis
FDA slaps Akorn plant with Form 483

11/06/2018

The regulatory body found issues at the drugmaker's New Jersey site, detailing 11 observations from an inspection in July and August.

Pharma Manufacturing

Join the discussion

Comments

FDA slaps Akorn plant with Form 483

The regulatory body found issues at the drugmaker's New Jersey site,…

QbD and Drug Packaging and Delivery: A Guide to Creating Safer Components

The increase in injectable biologic and biosimilar treatments is requiring…

BMS gets ready to layoff employees, shutter operations at ZymoGenetics facility

Operations at Seattle-based ZymoGenetics, which is owned by Bristol-Myers…

Sandoz recalls China-made blood pressure drug

Novartis said its Sandoz division is recalling one lot of losartan tablets…

AbbVie sues England’s NHS

Abbvie is claiming England's National Health Service (NHS) breached…

Report: Pfizer offering early retirement to some U.S. employees

With layoffs looming, Pfizer has reportedly offered eligible employees in…

Two former drug executives headed to prison

Former executives from Valeant Pharmaceuticals International and Philidor…

FDA slaps Akorn plant with Form 483

The regulatory body found issues at the drugmaker's New Jersey site,…

Trump proposes “revolutionary” Medicare model

In today’s speech at the Department of Health and Human Services,…

Novartis scraps U.S. filing for biosimilar rituximab

Novartis International AG’s Sandoz division will abandon its quest to…

Top 10 Selling Drugs in 2024

Which drugs will reign supreme in six years? It’s not too soon to roll…

Mylan plant hit with FDA Form 483 for cleaning practices

A West Virginia plant owned by Mylan Pharmaceuticals has been issued a…

Puerto Rico Pharma: Battered but Unbroken

One year after Hurricane Maria, Puerto Rico's pharma industry is standing…

Shrinking Big Pharma

Why building smaller manufacturing plants is the next big thing

2018 Pharma Innovation Awards

A much-deserved celebration of manufacturing technologies, hand-picked by…

Weighing and Dispensing: Do it Right

The weighroom is the entry point to manufacturing and a transition point…

CAPA and Root Cause Analysis

Recent FDA Warning Letters have cited insufficient corrective and…

Annual Product Reviews: How to Conduct an Effective Annual Product Quality Review

More than just a regulatory requirement, an APR helps the manufacturer to…

USP Updates <61> and <62> for Microbial Testing of Non-Steriles

Significant changes include more clarity on enumberation and specified…

Serialization and the Drug Quality & Security Act

The supply chain for genuine pharmaceuticals has grown longer, and every…